Latest news with #ASC30
Yahoo
4 hours ago
- Business
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc.
Associated Press
8 hours ago
- Business
- Associated Press
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ( NCT06427590 ) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity ( NCT06972992 ) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] View original content: SOURCE Ascletis Pharma Inc.
Yahoo
9 hours ago
- Business
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-04-2025
- Health
- Yahoo
Ascletis' oral GLP-1RA shows weight loss potential in early trial
Ascletis has announced its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved early weight loss in a Phase Ib trial and is now preparing to progress to a Phase IIa study. The China-based biotech's once-daily tablet ASC30 demonstrated a placebo-adjusted mean body weight reduction from baseline of up to 6.5% after four weeks of treatment. The company's stock, listed on the Hong Kong Stock Exchange (HKSE) has risen 4.55% today following the announcement. Despite this rise, the stock price has still not yet recovered from the hit it took after Donald Trump announced sweeping global tariffs on 2 April, with the company's stock continuing to fall as both China and the US continued to respond with reciprocal tariffs. The update follows a turbulent week in the oral obesity drug space, highlighted by a surge in Eli Lilly's stock after the company reported successful data from the first of seven anticipated Phase III readouts in 2025 for its oral GLP-1RA orforglipron. Meanwhile, Pfizer dropped the development of its oral weight loss candidate danuglipron after a drug-induced liver injury. Ascletis conducted the US Food and Drug Administration (FDA) approved Phase Ib multiple ascending dose (MAD) study (NCT06680440), in the US, with plans for the Phase IIa trial also submitted to the FDA. Patients enrolled were classified as obese and split into three cohorts each with a different weekly titration scheme. In the first cohort, mid-starting dose with slow titration, (2mg, 5mg, 10mg, and 20mg), there was a 4.5% placebo-adjusted mean body weight reduction, with the benefit of no vomiting seen in this dose group. The maximum weight loss recorded in this group was 7.6%. In the second group, mid-starting dose and normal titration (2mg, 10mg, 20mg, and 40mg), a 6.5% placebo-adjusted mean body weight reduction was recorded. The maximum weight loss reported in this arm was 9.1%. In the third cohort, the high-starting dose and fast titration (5mg, 15mg, 30mg, 60mg), there was a placebo-adjusted mean body weight reduction from baseline of 5.0%, with a maximum body weight reduction from baseline of 9.3%. Ascletis said that in the third arm, there were two outliers, each with a body weight reduction of 1.8% from baseline, which was not observed in the lower dose schemes. Excluding these two outliers, placebo-adjusted mean body weight reduction from baseline in the high-dose cohort was 6.1%. In all treatment arms, no weight plateau was observed. Meanwhile, in the placebo arm, mean body weight increase from baseline was 0.2%. Ascletis says that the drug was generally safe and well tolerated in both the lower dose arms, with 'comparable gastrointestinal tolerability to orforglipron'. The majority of gastrointestinal-related adverse events (AEs) were mild and short-lived. In the lowest dose cohort, there were no incidents of vomiting. While gastrointestinal tolerability in the high-dose arm was lower, Ascletis said there were still no serious AEs observed in any cohort. For the 13-week Phase IIa trial, Ascletis plans to use a "lower starting dose and slower titration" dosing schedule. The application for the study has been submitted to the FDA, with the company hoping to initiate the study at the beginning of the third quarter of 2025. In March, Ascletis announced data from its subcutaneous weight loss therapy ASC47 which is designed to preserve muscle mass. The data supports a monthly or twice-monthly dosing regimen of the selective small molecule agonist. "Ascletis' oral GLP-1RA shows weight loss potential in early trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
